official notice
decision of a delegate of the commissioner of patents
Application : No. 656735 in the name of Hoechst Aktiengesellschaft
Title: Synergistic Herbicidal Agents
Action: Opposition under section 59 of the Patents Act 1990 by Monsanto Company
Decision: Issued .
Abstract
Novelty:The claims defined a selection over the known art. The claims will lack novelty only if a prior document clearly shows the claimed combination of surfactant and herbicide has been made and that the surfactant acts as a synergist or enhances the activity of the herbicide.
Claims 1, 2 and 10 to and 11 lack novelty in light of EP 255 760. Example 2 of the citation is a clear disclosure that the combination of the claimed surfactant with a claimed herbicide has been made and the citation clearly discloses that the surfactant is incorporated to enhance the biological activity of the active agent.
Manner of Manufacture:
The claims define a manner of manufacture according to section 6 of the Statute of Monopolies. The use of surfactants according to the invention as synergists did not simply amount to the verification of an immediately predictable property of a known group of surfactants. The applicant had demonstrated that the surfactants achieved an improved result.
Inventive Step: The improved results provided by the invention were not immediately predictable. Rather, it appears to have been the result of inventive research, as per Beecham Group Ltd.’s (Amoxycillin) Application [1980] RPC 261
Section 40:The specific herbicides and surfactant reported in the examples of the specification provided sufficient basis for the claims. It was reasonable to extrapolate from the results given in the examples to the class of surfactants and herbicides claimed. The examples also supported the claims in the description of improved performance from the surfactants of the invention. The claims were clear and succinct and fairly based, and the invention was fully described.
patents act 1990
decision of a delegate of the commissioner of patents
Re:Patent Application No. 656735 by Hoechst Aktiengesellschaft and an opposition under section 59 of the Patents Act 1990 by Monsanto Company
background
Patent application 83863/91 by Hoechst Aktiengesellschaft was filed on 13 September 1991. The application claims a priority date of 15 September 1990. The application was advertised accepted on 16 February 1995 as application 656735.
Monsanto Company opposed the application on 16 May 1995 and filed a statement of grounds and particulars on 15 August 1995.
The applicant proposed amendments to the complete specification on 23 February 1996. The amendments were allowed.
I heard the opposition in Melbourne on 3 September 1997. Hoechst were represented by Mr B. J. Hess of Counsel, assisted by Ms Karen Sinclair and Ms Carolyn Harris, Patent Attorneys of Watermark Patent & Trademark Attorneys, Melbourne. Monsanto were represented by Dr John Emmerson QC, assisted by Dr Bruce Wellington, Patent Attorney of E F Wellington & Co, Melbourne.
specification
The specification is titled “Synergistical herbicidal agents”.
“The invention relates to the technical field of plant protection agents. in…
Keep reading for free
Create a free CaseChat account to read Hoechst Aktiengesellschaft v Monsanto Company and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [1998] APO 13
- Decision Date
CaseChat Overview and Summary
Background
Background to the litigation
The matter came before the court as an opposition under section 59 of the Patents Act 1990. Patent application 83863/91 by Hoechst Aktiengesellschaft, which claims a priority date of 15 September 1990, was filed on 13 September 1991 and accepted as application 656735 on 16 February 1995. Monsanto Company opposed the application on 16 May 1995 and filed a statement of grounds and particulars on 15 August 1995. The applicant proposed amendments to the complete specification on 23 February 1996, which were allowed. The opposition was heard in Melbourne on 3 September 1997.
Decision
Reasons for decision
1. Whether claims 1, 2 and 10 to 11 of the patent application lack novelty in light of the prior art.
2. Whether the claims define a manner of manufacture according to section 6 of the Statute of Monopolies.
3. Whether the invention lacks an inventive step.
4. Whether the claims are fairly based on the specification and do they comply with section 40 of the Patents Act 1990.
Held
1. Claims 1, 2 and 10 to 11 of the patent application lack novelty in light of the prior art, specifically European Patent Application 255 760 (Kao Corporation).
2. The claims define a manner of manufacture according to section 6 of the Statute of Monopolies, as the improved results were not immediately predictable and were the result of inventive research.
3. The invention does not lack an inventive step, as the opponent has not shown that the invention was obvious in light of what was known before the priority date.
4. The claims are fairly based on the specification and comply with section 40 of the Patents Act 1990.
Ratio Decidendi
Legal Principle Established
The court found that claims 1, 2 and 10 to 11 of the patent application lacked novelty in light of the prior art, specifically European Patent Application 255 760 (Kao Corporation). The claims defined a manner of manufacture according to section 6 of the Statute of Monopolies as the improved results were not immediately predictable and were the result of inventive research. The court held that the opponent had not established that the invention was obvious in light of what was known before the priority date, and therefore, the invention did not lack an inventive step. Finally, the court concluded that the claims were fairly based on the specification and complied with section 40 of the Patents Act 1990.
The court relied on the principle that for a selection patent to be valid, the selection must be based on some substantial advantage gained or some substantial disadvantage avoided, the whole of the selected members must possess the advantage in question, and the selection must be in respect of a quality of a special character which may fairly be said to be peculiar to the selected group. The court found that the examples in the specification showed synergy between the claimed surfactants and the herbicides, and an improved performance in relation to other conventional wetting agents. The court also found that the examples and the specification as a whole provided support for the class of surfactants and range of herbicides defined in the claims.
The court distinguished prior art documents that disclosed the use of surfactants with herbicides to enhance the effect of the herbicide, as the claims of the opposed application were restricted to herbicides from the group consisting of leaf-acting selective herbicides and the leaf-acting non-selective herbicides glyphosate, paraquat, and diquat. The court found that the claims were novel over the prior art documents, as they were not clearly and unmistakably disclosed.
The court held that the claims defined a manner of manufacture within the meaning of section 6 of the Statute of Monopolies, as the improved results achieved by the use of the claimed surfactants on the claimed group of herbicides were not immediately predictable and were the result of inventive research. The court also found that the invention did not lack an inventive step, as the opponent had not shown that the invention was obvious in light of what was known before the priority date.
Finally, the court concluded that the claims were fairly based on the specification and complied with section 40 of the Patents Act 1990. The court found that the examples and the specification as a whole provided support for the class of surfactants and range of herbicides defined in the claims, and that the claims were sufficiently described and claimed the invention. The court also found that the exclusion of glufosinate from the claims was incorrectly placed, but did not invalidate the claim through lack of clarity.